Rockefeller Capital Management’s Galectin Therapeutics GALT Stock Holding History
Bought
Maintained
Sold
Other funds holding GALT
Rockefeller Capital Management's GALT Position: Q3 2026 in Review
Rockefeller Capital Management increased its Galectin Therapeutics (GALT) stake by 102% in Q3 2026, buying an estimated $17.3K and bringing the position to 8,864 shares worth $34.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3654.
Rockefeller Capital Management first reported a position in GALT in Q4 2019 and has held it in 18 quarters since. The position peaked at $49K in Q3 2021. 103 funds tracked by Wall St. Rank hold GALT as of Q3 2026.
- Rockefeller Capital Management held 8,864 shares of Galectin Therapeutics worth $34.4K as of Q3 2026.
- Rockefeller Capital Management bought 4,478 Galectin Therapeutics shares in Q3 2026, an estimated $17.3K.
- Galectin Therapeutics made up ﹤0.01% of Rockefeller Capital Management's portfolio in Q3 2026, its #3654 holding.
- Rockefeller Capital Management first reported a position in Galectin Therapeutics in Q4 2019 and has held it in 18 quarters since.
- Rockefeller Capital Management's Galectin Therapeutics position peaked at $49K in Q3 2021.
- 103 funds tracked by Wall St. Rank held Galectin Therapeutics as of Q3 2026.
Based on Rockefeller Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.